A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
- Author
- MENG ZHAO1 ; XUELIANG PAN2 ; RAMASWAMY, Bhuvaneswari1 ; LAYMAN, Rachel1 ; LUSTBERG, Maryam B1 ; MROZEK, Ewa1 ; MACRAE, Erin R1 ; WESOLOWSKI, Robert1 ; CAROTHERS, Sarah1 ; PUHALLA, Shannon3 ; SHAPIRO, Charles L1
[1] Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, The Ohio State University's Wexner Medical Center, Starling-Loving Hall, 320 W 10th Ave, Columbus, OH 43210, United States
[2] Center for Biostatistics, The Ohio State University, 2012 Kenny Road, Columbus, OH 43221, United States
[3] University of Pittsburgh Medical Center, 300 Halket Str. Suite 4628, Pittsburgh, PA 15123, United States - Source
Investigational new drugs. 2014, Vol 32, Num 6, pp 1285-1294, 10 p ; ref : 41 ref
- CODEN
- INNDDK
- ISSN
- 0167-6997
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Springer, New York, NY
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- Bevacizumab Docetaxel HER2 Metastatic breast cancer Trastuzumab
- Keyword (fr)
- Antiangiogénique Anticancéreux Association médicamenteuse Bévacizumab Cancer du sein Docétaxel Essai clinique phase II Facteur croissance endothélium vasculaire Gène erbB2 Gène onc cellulaire Homme Métastase Protooncogène Stade avancé Toxicité Traitement Trastuzumab Anti-HER2 Anti-VEGF Récepteur HER2 Anticorps monoclonal Antimitotique Cancer Dérivé du taxane Pathologie de la glande mammaire Pathologie du sein Tumeur maligne
- Keyword (en)
- Antiangiogenic agent Antineoplastic agent Drug combination Bevacizumab Breast cancer Docetaxel Phase II trial Vascular endothelium growth factor erbB2 Gene C-Onc gene Human Metastasis Protooncogene Advanced stage Toxicity Treatment Trastuzumab Human Epidermal growth factor Receptor 2 Monoclonal antibody Antimitotic Cancer Taxane derivatives Mammary gland diseases Breast disease Malignant tumor
- Keyword (es)
- Antiangiogenico Anticanceroso Asociación medicamentosa Bevacizumab Cáncer del pecho Docetaxel Ensayo clínico fase II Factor crecimiento endotelio vascular Gen erbB2 Gen onc celular Hombre Metástasis Protooncogen Estadio avanzado Toxicidad Tratamiento Trastuzumab Anticuerpo monoclonal Antimitótico Cáncer Taxane derivado Glándula mamaria patología Seno patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Pharmacological treatments Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 29026939
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s10637-014-0122-5 
https://dx.doi.org/10.1007/s10637-014-0122-5
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-014-0122-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"Investigational new drugs\";s:9:\"\u0000*\u0000stitle\";s:17:\"Invest. new drugs\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"32\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1285\";s:8:\"\u0000*\u0000epage\";s:4:\"1294\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6997\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MENG ZHAO\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"XUELIANG PAN\";i:1;s:23:\"RAMASWAMY, Bhuvaneswari\";i:2;s:14:\"LAYMAN, Rachel\";i:3;s:18:\"LUSTBERG, Maryam B\";i:4;s:11:\"MROZEK, Ewa\";i:5;s:14:\"MACRAE, Erin R\";i:6;s:18:\"WESOLOWSKI, Robert\";i:7;s:16:\"CAROTHERS, Sarah\";i:8;s:16:\"PUHALLA, Shannon\";i:9;s:18:\"SHAPIRO, Charles L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"INNDDK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-014-0122-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"Investigational new drugs\";s:9:\"\u0000*\u0000stitle\";s:17:\"Invest. new drugs\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"32\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1285\";s:8:\"\u0000*\u0000epage\";s:4:\"1294\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6997\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MENG ZHAO\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"XUELIANG PAN\";i:1;s:23:\"RAMASWAMY, Bhuvaneswari\";i:2;s:14:\"LAYMAN, Rachel\";i:3;s:18:\"LUSTBERG, Maryam B\";i:4;s:11:\"MROZEK, Ewa\";i:5;s:14:\"MACRAE, Erin R\";i:6;s:18:\"WESOLOWSKI, Robert\";i:7;s:16:\"CAROTHERS, Sarah\";i:8;s:16:\"PUHALLA, Shannon\";i:9;s:18:\"SHAPIRO, Charles L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"INNDDK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-014-0122-5\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-014-0122-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"Investigational new drugs\";s:9:\"\u0000*\u0000stitle\";s:17:\"Invest. new drugs\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"32\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1285\";s:8:\"\u0000*\u0000epage\";s:4:\"1294\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6997\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MENG ZHAO\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"XUELIANG PAN\";i:1;s:23:\"RAMASWAMY, Bhuvaneswari\";i:2;s:14:\"LAYMAN, Rachel\";i:3;s:18:\"LUSTBERG, Maryam B\";i:4;s:11:\"MROZEK, Ewa\";i:5;s:14:\"MACRAE, Erin R\";i:6;s:18:\"WESOLOWSKI, Robert\";i:7;s:16:\"CAROTHERS, Sarah\";i:8;s:16:\"PUHALLA, Shannon\";i:9;s:18:\"SHAPIRO, Charles L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"INNDDK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-014-0122-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"Investigational new drugs\";s:9:\"\u0000*\u0000stitle\";s:17:\"Invest. new drugs\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"32\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1285\";s:8:\"\u0000*\u0000epage\";s:4:\"1294\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6997\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MENG ZHAO\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"XUELIANG PAN\";i:1;s:23:\"RAMASWAMY, Bhuvaneswari\";i:2;s:14:\"LAYMAN, Rachel\";i:3;s:18:\"LUSTBERG, Maryam B\";i:4;s:11:\"MROZEK, Ewa\";i:5;s:14:\"MACRAE, Erin R\";i:6;s:18:\"WESOLOWSKI, Robert\";i:7;s:16:\"CAROTHERS, Sarah\";i:8;s:16:\"PUHALLA, Shannon\";i:9;s:18:\"SHAPIRO, Charles L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"INNDDK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-014-0122-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"Investigational new drugs\";s:9:\"\u0000*\u0000stitle\";s:17:\"Invest. new drugs\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"32\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1285\";s:8:\"\u0000*\u0000epage\";s:4:\"1294\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6997\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MENG ZHAO\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"XUELIANG PAN\";i:1;s:23:\"RAMASWAMY, Bhuvaneswari\";i:2;s:14:\"LAYMAN, Rachel\";i:3;s:18:\"LUSTBERG, Maryam B\";i:4;s:11:\"MROZEK, Ewa\";i:5;s:14:\"MACRAE, Erin R\";i:6;s:18:\"WESOLOWSKI, Robert\";i:7;s:16:\"CAROTHERS, Sarah\";i:8;s:16:\"PUHALLA, Shannon\";i:9;s:18:\"SHAPIRO, Charles L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"INNDDK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
